Prostate Cancer Diagnostics
Advertisement
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS.
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.
Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.
The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.
Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. David Morris discusses the emerging role of copper-based PSMA imaging agents, specifically 64Cu-SAR-bisPSMA.
Clarity Pharmaceuticals announced that the first two participants in Co-PSMA have been dosed with its proprietary medication.
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.